CS-0777-P
CS-0777-P, the phosphorylated form of CS-0777, acts as a potent and selective modulator of the S1P receptor-1 (S1P1). It exhibits approximately 320-fold higher agonist activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. In pharmacological studies, CS-0777-P demonstrated significant effects in vitro as an S1P1 and S1P3 agonist, leading to lowered peripheral blood lymphocyte counts and suppressive effects on experimental autoimmune encephalomyelitis (EAE) in rats. Pharmacokinetic studies in rats revealed rapid lymphocyte count reductions following oral administration, making CS-0777 a promising candidate currently undergoing clinical trials for the treatment of multiple sclerosis (MS).
For research use only. We do not sell to patients.
- CAS No.: 840523-39-9
- Formula: C21H31N2O5P
- Molecular Weight:422.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | EC50 |
1.1 nM
Compound: 4, CS-0777-P
|
Agonist activity at human S1P1 receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
Agonist activity at human S1P1 receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
|
[PMID: 24900318] |
| CHO-K1 | EC50 |
1.1 nM
Compound: 4, CS-0777-P
|
Agonist activity at human S1P1 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
Agonist activity at human S1P1 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
|
[PMID: 22405291] |
| CHO-K1 | EC50 |
1.8 nM
Compound: 4, CS-0777-P
|
Agonist activity at rat S1P1 receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
Agonist activity at rat S1P1 receptor expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
|
[PMID: 24900318] |
| CHO-K1 | EC50 |
1.8 nM
Compound: 4, CS-0777-P
|
Agonist activity at rat S1P1 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
Agonist activity at rat S1P1 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
|
[PMID: 22405291] |
| CHO-K1 | EC50 |
200 nM
Compound: 4, CS-0777-P
|
Agonist activity at rat S1P3R expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
Agonist activity at rat S1P3R expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
|
[PMID: 24900318] |
| CHO-K1 | EC50 |
200 nM
Compound: 4, CS-0777-P
|
Agonist activity at rat S1P3 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
Agonist activity at rat S1P3 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
|
[PMID: 22405291] |
| CHO-K1 | EC50 |
350 nM
Compound: 4, CS-0777-P
|
Agonist activity at human S1P3R expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
Agonist activity at human S1P3R expressed in CHO-K1 cells by [35S]GTPgammaS binding assay
|
[PMID: 24900318] |
| CHO-K1 | EC50 |
350 nM
Compound: 4, CS-0777-P
|
Agonist activity at human S1P3 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
Agonist activity at human S1P3 receptor expressed in CHO-K1 cells assessed as induction of GTPgammaS binding
|
[PMID: 22405291] |
Chemical Information
-
CAS No. 840523-39-9
-
Molecular Weight 422.46
-
Formula C21H31N2O5P
-
SMILES
O=P(O)(O)OC[C@](C)(N)CCC1=CC=C(C(CCCC2=CC=C(C=C2)C)=O)N1C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)